PSYK
Investment Objective
PSYK seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. Currently, the ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses.
Fund Details
Ticker
PSYK
Inception Date
January 26, 2021
Net Assets ?
$9,785,490
As at December 01, 2023
Consolidated Prior Day Volume ?
9 150
For December 01, 2023
Average Daily Trading Volume Over a 12 Month Period ?
2,597
As at December 01, 2023
Exchange
NEO Exchange
Investment Manager
Horizons ETFs Management (Canada) Inc.
Eligibility
All Registered and Non-Registered Investment Accounts
Benchmark
Bloomberg Index Ticker
HPSYKTR
Management Fee
0.85%
(Plus applicable sales tax)
Management Expense Ratio ?
1.16%
As at June 30, 2023
Currency
CAD
Currency Hedging
N/A
LEI ?
5493003DII1O2LYBVQ81
Distribution Metrics
Most Recent Distributions Per Unit
$0.03023
12-Month Trailing Yield ?
-- %
Distribution Frequency
Record Date
September 29, 2021
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
| 1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
|---|---|---|---|---|---|---|---|---|---|
| Horizons Psychedelic Stock Index ETF | -4.62 | -23.62 | -10.09 | -14.76 | -31.70 | -- | -- | -- | -50.17 | North American Psychedelics Index | -4.07 | -22.75 | -7.44 | -7.64 | -25.73 | -- | -- | -- | -48.61 |
**Fund performance since inception on January 26, 2021, as at October 31, 2023
Calendar Year Performance (%) *
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
|
Horizons Psychedelic Stock Index ETF |
-- | -- | -- | -- | -- | -- | -- | -63.48 | North American Psychedelics Index | -- | -- | -- | -- | -- | -- | -- | -62.93 |
Distributions
| Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
|---|---|---|---|---|---|---|
| 2021 | 09/28/2021 | 09/29/2021 | 10/13/2021 | 0.03023 | — |
Top 10 Holdings
As at November 24, 2023| Security Name | Weight |
|---|---|
| CYBIN INC . | 18.30% |
| FSD PHARMA INC CL B SUB VTG NEW | 12.56% |
| Relmada Therapeutics Inc | 10.06% |
| ATAI LIFE SCIENCES NV . | 9.25% |
| MIND MEDICINE MINDMED INC | 9.21% |
| COMPASS PATHWAYS PLC ADR | 9.10% |
| GH RESEARCH PLC . | 8.61% |
| Abbvie Inc | 6.33% |
| Johnson & Johnson | 6.05% |
| Numinus Wellness Inc | 5.41% |
Holdings are subject to change. Download full prior business day: Holdings
Education
Regulatory and Legal
At a Glance
Investment Objective
PSYK seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. Currently, the ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses.
Product Facts
Fund Details
Ticker
PSYK
Inception Date
January 26, 2021
Net Assets ?
$9,785,490
As at December 01, 2023
Consolidated Prior Day Volume ?
9 150
ForDecember 01, 2023
Average Daily Trading Volume Over a 12 Month Period ?
2,597
As at December 01, 2023
Exchange
NEO Exchange
Investment Manager
Horizons ETFs Management (Canada) Inc.
Eligibility
All Registered and Non-Registered Investment Accounts
Benchmark
Bloomberg Index Ticker
HPSYKTR
Management Fee
0.85%
(Plus applicable sales tax)
Management Expense Ratio ?
1.16%
As at June 30, 2023
Currency
CAD
Currency Hedging
N/A
LEI ?
5493003DII1O2LYBVQ81
Distribution Metrics
As at December 01, 2023
Most Recent Distributions Per Unit
0.03023
Annualized Distribution Yield ?
-- %
As at December 01, 2023
12-Month Trailing Yield ?
-- %
Distribution Frequency
Record Date
September 29, 2021
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Performance & Distributions
Annualized Performance (%) *
| 1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
|---|---|---|---|---|---|---|---|---|---|
| Horizons Psychedelic Stock Index ETF | -4.62 | -23.62 | -10.09 | -14.76 | -31.70 | -- | -- | -- | -50.17 | North American Psychedelics Index | -4.07 | -22.75 | -7.44 | -7.64 | -25.73 | -- | -- | -- | -48.61 |
**Fund performance since inception on January 26, 2021, as at October 31, 2023
Calendar Year Performance (%)
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Horizons Psychedelic Stock Index ETF | -- | -- | -- | -- | -- | -- | -- | -63.48 | North American Psychedelics Index | -- | -- | -- | -- | -- | -- | -- | -62.93 |
Distributions
| Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
|---|---|---|---|---|---|---|
| 2021 | 09/28/2021 | 09/29/2021 | 10/13/2021 | 0.03023 |
Holdings
Top 10 Holdings
As at November 24, 2023| Security Name | Weight |
|---|---|
| CYBIN INC . | 18.30% |
| FSD PHARMA INC CL B SUB VTG NEW | 12.56% |
| Relmada Therapeutics Inc | 10.06% |
| ATAI LIFE SCIENCES NV . | 9.25% |
| MIND MEDICINE MINDMED INC | 9.21% |
| COMPASS PATHWAYS PLC ADR | 9.10% |
| GH RESEARCH PLC . | 8.61% |
| Abbvie Inc | 6.33% |
| Johnson & Johnson | 6.05% |
| Numinus Wellness Inc | 5.41% |
Holdings are subject to change. Download full prior business day: Holdings
Documents
